Last news
nCino Reports Fourth Quarter and Fiscal Year 2025 Financial Results

nCino Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Notified -...

nCino Announces Stock Repurchase Program

nCino Announces Stock Repurchase Program

Notified -...

Gluco6 Reviews (DOCTOR INVESTIGATED): Is This Blood Sugar Breakthrough Too Good to Be True?

Gluco6 Reviews (DOCTOR INVESTIGATED): Is This Blood Sugar Breakthrough Too Good to Be True?

Notified -...

Prime Biome (INVESTIGATIVE REPORT): Does This Trending Gut Reset Supplement Actually Deliver Real Results?

Prime Biome (INVESTIGATIVE REPORT): Does This Trending Gut Reset Supplement Actually Deliver Real Results?

Notified -...

VCI Global Announces 1-for-20 Reverse Stock Split

VCI Global Announces 1-for-20 Reverse Stock Split

Notified -...

AI-Media Partners with AudioShake to Revolutionize Live Sports Audio and AI Voice Translation

AI-Media Partners with AudioShake to Revolutionize Live Sports Audio and AI Voice Translation

Notified -...

Vicor to present at WCX 2025 in Detroit

Vicor to present at WCX 2025 in Detroit

Notified -...

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

Notified -...

1 ... 229 230 231 232 233 234 235 236 237 ... 992
menu
menu